骨关节炎（DMOAD）治疗药物的研发：现有证据。
The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
机构信息
Rheumatology Department, Royal North Shore Hospital, and Institute of Bone and Joint Research, Kolling Institute, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
Department of Physical Medicine and Rehabilitation, Mandalay General Hospital, University of Medicine, Mandalay, Mandalay, Myanmar.
出版信息
Drug Des Devel Ther. 2021 Jul 6;15:2921-2945. doi: 10.2147/DDDT.S295224. eCollection 2021.
Osteoarthritis (OA) is a complex heterogeneous articular disease with multiple joint tissue involvement of varying severity and no regulatory-agency-approved disease-modifying drugs (DMOADs). In this review, we discuss the reasons necessitating the development of DMOADs for OA management, the classifications of clinical phenotypes or molecular/mechanistic endotypes from the viewpoint of targeted drug discovery, and then summarize the efficacy and safety profile of a range of targeted drugs in Phase 2 and 3 clinical trials directed to cartilage-driven, bone-driven, and inflammation-driven endotypes. Finally, we briefly put forward the reasons for failures in OA clinical trials and possible steps to overcome these barriers.
骨关节炎（OA）是一种复杂的异质性关节疾病，多个关节组织受累，严重程度不一，且无监管机构批准的疾病修饰药物（DMOAD）。在这篇综述中，我们讨论了开发 OA 管理 DMOAD 的必要性原因，从靶向药物发现的角度讨论了临床表型或分子/机制表型的分类，然后总结了一系列针对软骨驱动、骨驱动和炎症驱动表型的靶向药物在 2 期和 3 期临床试验中的疗效和安全性概况。最后，我们简要提出了 OA 临床试验失败的原因和克服这些障碍的可能步骤。
Zotero 插件